Skandinaviska Enskilda Banken AB publ Purchases 363 Shares of Veracyte, Inc. (NASDAQ:VCYT)

Skandinaviska Enskilda Banken AB publ grew its position in shares of Veracyte, Inc. (NASDAQ:VCYT) by 1.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,796 shares of the biotechnology company’s stock after buying an additional 363 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Veracyte were worth $991,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently bought and sold shares of the business. Fifth Third Bancorp lifted its position in shares of Veracyte by 4.0% during the 2nd quarter. Fifth Third Bancorp now owns 5,508 shares of the biotechnology company’s stock worth $220,000 after buying an additional 214 shares in the last quarter. Great West Life Assurance Co. Can increased its stake in shares of Veracyte by 10.2% during the 1st quarter. Great West Life Assurance Co. Can now owns 3,916 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 361 shares during the last quarter. Lazard Asset Management LLC increased its stake in shares of Veracyte by 34.8% during the 1st quarter. Lazard Asset Management LLC now owns 1,677 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 433 shares during the last quarter. Amalgamated Bank increased its stake in shares of Veracyte by 5.4% during the 1st quarter. Amalgamated Bank now owns 9,435 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 483 shares during the last quarter. Finally, NEXT Financial Group Inc increased its stake in shares of Veracyte by 21.4% during the 2nd quarter. NEXT Financial Group Inc now owns 3,005 shares of the biotechnology company’s stock worth $120,000 after purchasing an additional 529 shares during the last quarter.

In other Veracyte news, insider Bonnie H. Anderson sold 2,600 shares of the company’s stock in a transaction that occurred on Friday, September 17th. The shares were sold at an average price of $50.18, for a total transaction of $130,468.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bonnie H. Anderson sold 1,900 shares of the company’s stock in a transaction that occurred on Friday, September 10th. The shares were sold at an average price of $50.03, for a total transaction of $95,057.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,031 shares of company stock worth $858,967. Corporate insiders own 8.30% of the company’s stock.

A number of research analysts recently weighed in on VCYT shares. SVB Leerink lifted their price objective on shares of Veracyte from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Needham & Company LLC raised their price target on shares of Veracyte from $54.00 to $55.00 and gave the company a “buy” rating in a report on Friday, July 30th. Morgan Stanley cut their price target on shares of Veracyte from $45.00 to $42.00 and set an “underweight” rating for the company in a report on Friday, July 30th. Raymond James raised their price target on shares of Veracyte from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, June 28th. Finally, Zacks Investment Research downgraded shares of Veracyte from a “buy” rating to a “hold” rating in a report on Friday, July 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $52.50.

VCYT stock opened at $49.17 on Wednesday. The firm’s 50-day moving average price is $43.90 and its two-hundred day moving average price is $44.04. Veracyte, Inc. has a 12-month low of $28.82 and a 12-month high of $86.03. The stock has a market capitalization of $3.48 billion, a price-to-earnings ratio of -48.68 and a beta of 0.77.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings results on Thursday, July 29th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.12. Veracyte had a negative net margin of 40.06% and a negative return on equity of 4.05%. The company had revenue of $55.11 million for the quarter, compared to analysts’ expectations of $47.73 million. On average, research analysts expect that Veracyte, Inc. will post -0.61 EPS for the current fiscal year.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.

See Also: What are the disadvantages of after-hours trading?

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.